858-449-1310 contact@somatek.com

Monoclonal for Alzheimer’s

On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...

San Diego #5 US Biopharma Cluster in 2020

A list of the ten top ranking biopharmaceutical clusters in the US was recently compiled by Genetic Engineering News. The list is based on available 2020 data for NIH funding, venture capital funding, patents, lab space and jobs. San Diego made #5 of the list. Yay!...

Honoring our friend and mentor, Ralph Reisfeld

Our dear friend and mentor, Ralph, passed in December after a long and fruitful life in science. Ralph leaves an important legacy as a pioneer in cancer immunotherapy and as a valued mentor, colleague and friend to many. We will miss him very much and want to share an...

Cold chain is a hot topic among investors

The Pfizer and BioNTech vaccine against COVID-19 received an emergency use authorization from the FDA last Friday, and thousands of doses are being rolled out across the country this week. But the vaccine, which must be stored at between -80 and -60 degrees Celsius, necessitates the utilization of a “cold chain” to keep it within this temperature range from the moment it leaves the manufacturing site to just before it is administered to a patient.

Pfizer reports coronavirus vaccine with more than 90% efficacy

In what could prove to be a turning point in the fight against COVID-19, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced yesterday that one of their coronavirus vaccines is more than 90% effective at preventing the viral disease, according to new data from its Phase III trial. They are predicting that they will have the requisite safety data for an Emergency Use Authorization from the FDA before the end of the month.